nach oben

Erschienen in:

13.04.2022 | Osteosarkom | CME-Topic

Das kraniofaziale Osteosarkom: eine interdisziplinäre Herausforderung

verfasst von: Prof. Dr. Stefan Bielack, Stefanie Hecker-Nolting, Leo Kager, Thorsten Langer, Claudia Blattmann

Erschienen in: best practice onkologie | Ausgabe 4/2022

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Osteosarkom (OS) ist der häufigste maligne primäre Knochentumor. Er tritt v. a. an den Extremitäten junger Menschen auf, kann jedoch auch kraniofazial entstehen, mit entscheidenden epidemiologischen, therapeutischen und prognostischen Besonderheiten. Die Therapie des kraniofazialen Osteosarkoms (CFOS) wird maßgeblich von der Operation geprägt, die im Gesunden erfolgen muss, um eine realistische Heilungschance zu gewähren. Andere lokaltherapeutische Verfahren wie innovative Strahlentherapien sind zwar beim CFOS häufig erforderlich, aber deutlich nachrangig. Adjuvante chemotherapeutische Verfahren können auch beim CFOS zum Einsatz kommen und werden von europäischen Leitlinien empfohlen. Nach der Therapie bedürfen Betroffene einer lebenslangen, risikoadaptierten Nachsorge.

Isakoff MS, Bielack SS, Meltzer P et al (2015) Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol 33(27):3029–3035. https://doi.org/10.1200/JCO.2014.59.4895 CrossRefPubMedPubMedCentral

Bielack SS, Hecker-Nolting S, Blattmann C et al (2016) Advances in the management of osteosarcoma. F1000Res 5:2767. https://doi.org/10.12688/f1000research.9465.1 CrossRefPubMedPubMedCentral

Smrke A, Anderson PM, Gulia A et al (2021) Future directions in the treatment of osteosarcoma. Cells 10(1):172. https://doi.org/10.3390/cells10010172 CrossRefPubMedPubMedCentral

Jaffe N (2014) Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma. Adv Exp Med Biol 804:1–30. https://doi.org/10.1007/978-3-319-04843-7_1 CrossRefPubMed

Smeland S, Bielack SS, Whelan J et al (2019) Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS‑1 (European and American Osteosarcoma Study) cohort. Eur J Cancer 109:36–50. https://doi.org/10.1016/j.ejca .2018.11.027 CrossRef

Yamanaka R, Hayano A (2017) Secondary craniofacial sarcomas following retinoblastoma: a systematic review. World Neurosurg 101:722–730.e4. https://doi.org/10.1016/j.wneu.2017.02.031 CrossRefPubMed

Casali PG, Bielack S, Abecassis N et al (2018) ESMO Guidelines Committee, PaedCan and ERN EURACAN bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl4):iv79–iv95. https://doi.org/10.1093/annonc/mdy310

Marina NM, Smeland S, Bielack SS et al (2016) Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol 17(10):1396–1408. https://doi.org/10.1016/S1470-2045(16)30214-5 CrossRefPubMedPubMedCentral

Cooperative German-Austrian-Swiss Osteosarcoma Study Group, Kager L, Zoubek A, Pötschger U et al (2003) Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 21(10):2011–2018. https://doi.org/10.1200/JCO.2003.08.132 CrossRef

10.

Kempf-Bielack B, Bielack SS, Jürgens H et al (2005) Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23(3):559–568. https://doi.org/10.1200/JCO.2005.04.063 CrossRefPubMed

11.

Bielack SS, Kempf-Bielack B, Branscheid D et al (2009) Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol 27(4):557–565. https://doi.org/10.1200/JCO.2008.16.2305 CrossRefPubMed

12.

Gaspar N, Marques da Costa ME, Fromigue O et al (2020) Recent advances in understanding osteosarcoma and emerging therapies. Fac Rev 9:18. https://doi.org/10.12703/r/9-18 CrossRefPubMedPubMedCentral

13.

Smeele LE, Kostense PJ, van der Waal I et al (1997) Effect of chemotherapy on survival of craniofacial osteosarcoma: a systematic review of 201 patients. J Clin Oncol 15(1):363–367. https://doi.org/10.1200/JCO.1997.15.1.363 CrossRefPubMed

14.

Cooperative Osteosarcoma Study Group COSS, Jasnau S, Meyer U, Potratz J et al (2008) Craniofacial osteosarcoma Experience of the cooperative German-Austrian-Swiss osteosarcoma study group. Oral Oncol 44(3):286–294. https://doi.org/10.1016/j.oraloncology.2007.03.001 CrossRef

15.

Boon E, van der Graaf WT, Gelderblom H et al (2017) Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults. Head Neck 39(1):140–146. https://doi.org/10.1002/hed.24556 CrossRefPubMed

16.

Bielack SS, Kempf-Bielack B, Delling G et al (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20(3):776–790. https://doi.org/10.1200/JCO.2002.20.3.776 CrossRefPubMed

17.

Guadagnolo BA, Zagars GK, Raymond AK et al (2009) Osteosarcoma of the jaw/craniofacial region: outcomes after multimodality treatment. Cancer 115(14):3262–3270. https://doi.org/10.1002/cncr.24297 CrossRefPubMed

18.

Bouaoud J, Beinse G, Epaillard N et al (2019) Lack of efficacy of neoadjuvant chemotherapy in adult patients with maxillo-facial high-grade osteosarcomas: A French experience in two reference centers. Oral Oncol 95:79–86. https://doi.org/10.1016/j.oraloncology.2019.06.011 CrossRefPubMed

19.

Enneking WF, Spanier SS, Goodman MA (1980) A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 153:106–120 CrossRef

20.

Ciernik IF, Niemierko A, Harmon DC et al (2011) Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer 117(19):4522–4530. https://doi.org/10.1002/cncr.26037 CrossRefPubMed

21.

Seidensaal K, Mattke M, Haufe S et al (2021) The role of combined ion-beam radiotherapy (CIBRT) with protons and carbon ions in a multimodal treatment strategy of inoperable osteosarcoma. Radiother Oncol. https://doi.org/10.1016/j.radonc.2021.01.029 CrossRefPubMed

22.

Bielack S, Cable MG, Gorlick R, Hecker-Nolting S, Kager L, Marina N, Randall RL, Whelan J et al (2021) Osteosarcoma—approach to therapy. C. A. S. Arndt (ed.), sarcomas of bone and soft tissues in children and adolescents. Cancer Treat Res. https://doi.org/10.1007/978-3-030-51160-9_8 CrossRef

23.

EURAMOS‑1 investigators, Bielack SS, Smeland S, Whelan JS et al (2015) Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS‑1 Good Response Randomized Controlled Trial. J Clin Oncol 33(20):2279–2287. https://doi.org/10.1200/JCO.2014.60.0734 CrossRef

24.

Ferrari S, Bielack SS, Smeland S et al (2018) EURO‑B.O.S.S.: a European study on chemotherapy in bone-sarcoma patients aged over 40: outcome in primary high-grade osteosarcoma. Tumori 104(1):30–36. https://doi.org/10.5301/tj.5000696 CrossRefPubMed

25.

Janeway KA, Grier HE (2010) Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol 11(7):670–678. https://doi.org/10.1016/S1470-2045(10)70062-0 CrossRefPubMed

26.

Langer T, Grabow D, Steinmann D et al (2017) Late effects and long-term follow-up after cancer in childhood. Oncol Res Treat 40(12):746–750. https://doi.org/10.1159/000484936 CrossRefPubMed

27.

Gebauer J, Baust K, Bardi E, Grabow D, Stein A, van der Pal HJ, Calaminus G, Langer T (2020) Guidelines for long-term follow-up after childhood cancer: practical implications for the daily work. Oncol Res Treat 43(3):61–69. https://doi.org/10.1159/000504200 CrossRefPubMed

28.

https://www.kinderkrebsinfo.de/sites/kinderkrebsinfo/content/e1676/e1738/e1756/e186197/NachsorgeEURAMOS-1160617_ger.pdf. Zugegriffen: 01.06.21

29.

Kaneuchi Y, Hakozaki M, Yamada H et al (2020) Very late relapse of high-grade osteosarcoma: a case report and review of the literature. Medicine 99(29):e21206. https://doi.org/10.1097/MD.0000000000021206 CrossRefPubMedPubMedCentral

30.

Mancilla TR, Iskra B, Aune GJ (2019) Doxorubicin-induced cardiomyopathy in children. Compr Physiol 9(3):905–931. https://doi.org/10.1002/cphy.c180017 CrossRefPubMedPubMedCentral

31.

Knijnenburg SL, Mulder RL, Schouten-Van Meeteren AY et al (2013) Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD008944.pub2 CrossRefPubMed

32.

Skinner R (2018) Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance. Pediatr Nephrol 33(2):215–225. https://doi.org/10.1007/s00467-017-3662-z CrossRefPubMed

33.

Moke DJ, Luo C, Millstein J et al (2021) Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study. Lancet Child Adolesc Health. https://doi.org/10.1016/S2352-4642(21)00020-1 CrossRefPubMed

34.

Dracham CB, Shankar A, Madan R (2018) Radiation induced secondary malignancies: a review article. Radiat Oncol J 36(2):85–94. https://doi.org/10.3857/roj.2018.00290.38 CrossRefPubMedPubMedCentral

35.

Winer ES (2020) Secondary acute myeloid leukemia: a primary challenge of diagnosis and treatment. Hematol Oncol Clin North Am 34(2):449–463. https://doi.org/10.1016/j.hoc.2019.11.003 CrossRefPubMed

36.

Kratz CP, Jongmans MC, Cavé H et al (2021) Predisposition to cancer in children and adolescents. Lancet Child Adolesc Health 5(2):142–154. https://doi.org/10.1016/S2352-4642(20)30275-3 CrossRefPubMed

37.

Bielack SS (2010) Osteosarcoma: time to move on? Eur J Cancer 46(11):1942–1945. https://doi.org/10.1016/j.ejca.2010.03.009 CrossRefPubMed

38.

Frisch S, Timmermann B (2017) The evolving role of proton beam therapy for sarcomas. Clin Oncol 29(8):500–506. https://doi.org/10.1016/j.clon.2017.04.034 CrossRef

Titel: Das kraniofaziale Osteosarkom: eine interdisziplinäre Herausforderung
verfasst von: Prof. Dr. Stefan Bielack
Stefanie Hecker-Nolting
Leo Kager
Thorsten Langer
Claudia Blattmann
Publikationsdatum: 13.04.2022
Verlag: Springer Medizin
Schlagwörter: Osteosarkom
Osteosarkom
Tumorchirurgie
Kiefersarkom
Strahlentherapie
Chemotherapie
MKG-Tumorchirurgie
Seltene Erkrankungen
Erschienen in: best practice onkologie / Ausgabe 4/2022
Print ISSN: 0946-4565
Elektronische ISSN: 1862-8559
DOI: https://doi.org/10.1007/s11654-022-00384-6

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2022

Prävention HPV-induzierter Erkrankungen durch prophylaktische Impfung

Editorial

Krebsprädispositionssyndrome – Wie erkennen, wie behandeln?

onko-aktuell

Wichtige Studien vom ASH 2021

HIV-assoziierte Neoplasien – eine kritische Bestandsaufnahme